These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28254730)

  • 21. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.
    Berger LA; Riesenberg H; Bokemeyer C; Atanackovic D
    Lung Cancer; 2013 Jun; 80(3):242-8. PubMed ID: 23453646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2016 Mar; 12(6):815-25. PubMed ID: 26829230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
    Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
    J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR mutations in patients with non small-cell lung cancer in Bulgaria and treatment with gefitinib.
    Damyanov D; Koynov K; Naseva E; Bichev S
    J BUON; 2015; 20(1):136-41. PubMed ID: 25778308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic treatment of brain metastases in non-small cell lung cancer.
    Page S; Milner-Watts C; Perna M; Janzic U; Vidal N; Kaudeer N; Ahmed M; McDonald F; Locke I; Minchom A; Bhosle J; Welsh L; O'Brien M
    Eur J Cancer; 2020 Jun; 132():187-198. PubMed ID: 32380429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ; Ou SH
    Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
    Bartolotti M; Franceschi E; Brandes AA
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G; Seto T; Takenoyama M; Ichinose Y
    Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
    Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.
    Johung KL; Yao X; Li F; Yu JB; Gettinger SN; Goldberg S; Decker RH; Hess JA; Chiang VL; Contessa JN
    Clin Cancer Res; 2013 Oct; 19(19):5523-32. PubMed ID: 23897899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients.
    Shepherd FA
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):41-3. PubMed ID: 27057666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    Kazandjian D; Blumenthal GM; Yuan W; He K; Keegan P; Pazdur R
    Clin Cancer Res; 2016 Mar; 22(6):1307-12. PubMed ID: 26980062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
    Russo A; Franchina T; Ricciardi GR; Picone A; Ferraro G; Zanghì M; Toscano G; Giordano A; Adamo V
    Oncotarget; 2015 Sep; 6(29):26814-25. PubMed ID: 26308162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing central nervous system metastases in non-small cell lung cancer.
    Krawczyk P; Duchnowska R; Nicoś M; Kowalski D; Wojas-Krawczyk K
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1077-1083. PubMed ID: 30198357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.